SCHEMBL23484580

SCHEMBL23484580

C[Si](C)(C)C#Cc1cc2ccc(C(F)(F)F)cc2cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.36
METAP2 P50579 1/20 0.36
ABL1 P00519 1/20 0.34
PIM1 P11309 1/20 0.33
PIM2 Q9P1W9 1/20 0.33
DGAT1 O75907 1/20 0.33
THRB P10828 1/20 0.33
GRM5 P41594 3/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
CTSS P25774 1/20 0.32
GRM4 Q14833 1/20 0.32
ESR1 P03372 1/20 0.32
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRA3 P34903 1/20 0.31
GABRA2 P47869 1/20 0.31
GABRA4 P48169 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22816507 0.80 PIM1 (0.38) ABL1PIM1GRM5GRM4NFKB1
SCHEMBL22815839 0.78 BACE1 (0.40) BACE1METAP2ABL1PIM1PIM2
SCHEMBL25067052 0.78 KMT2A (0.39) BACE1DGAT1GABRA1GABRG2GABRB3
SCHEMBL29624514 0.76 NOS3 (0.46) METAP2GRM5CTSSGABRA1GABRG2
SCHEMBL6159726 0.76 NOS3 (0.46) METAP2GRM5CTSSGABRA1GABRG2
SCHEMBL23484636 0.76 PIM1 (0.37) PIM1GRM5GRM4NFKB1PDE10A
SCHEMBL22815843 0.73 MAOB (0.47) ABL1THRBGRM5
SCHEMBL2749229 0.73 BACE1 (0.43) BACE1METAP2ABL1PIM1PIM2
SCHEMBL22815841 0.69 BACE1 (0.43) BACE1METAP2THRBGRM4ESR1
SCHEMBL30265902 0.69 BACE1 (0.56) BACE1METAP2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT BACE1 2333/4885METAP2 1155/4885ABL1 2838/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT BACE1 2333/4885METAP2 1155/4885ABL1 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.